BioRestorative Therapies has finished manufacturing the clinical supply for its BRTX-100 Phase 2 trial, a stem cell therapy targeting chronic lumbar disc disease. This milestone highlights the company's integrated regenerative medicine platform, which controls the entire manufacturing process to ensure quality and scalability. The therapy aims to provide a non-surgical treatment option for patients with chronic lower back pain. Completion of manufacturing supports ongoing clinical development and positions the company for future commercialization and cost efficiencies.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Blackrock CEO Larry Fink expressed strong optimism about market prospects over the next year, citing technology-driven productivity and margin expansion as key growth drivers. He noted that overall financial leverage is much lower than during the 200...
Velvet token fell about 18% in one day amid heavy selling, yet it remains the top gainer among the top 100 tokens with a 571% increase over the past 90 days. Despite $24 million exiting its perpetual Futures market in two weeks, bullish sentiment per...
